- Letters to the Editor
- Open Access
False-positive Legionella pneumophila antibodies in COVID-19 patients
Intensive Care Medicine Experimental volume 11, Article number: 29 (2023)
The number of patients with coronavirus disease 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has increased in China since the reopening. From December 30, 2022, to January 30, 2023, a total of 23 critically ill patients with COVID-19 were consecutively admitted to a medical intensive care unit of Peking Union Medical College Hospital. We detected Immunoglobulin M (IgM) of Legionella pneumophila (LP) serological antibody test in 14 (14/23, 60.9%) patients. However, the subsequently confirmative investigation of both Polymerase chain reaction (PCR) (14/14, 100%) from bronchoalveolar fluid (BALF) and urine antigen test (12/12, 100%) for LP were negative.
As shown in Fig. 1A, the characteristics and managements were similar between LP-IgM positive and negative groups. Meanwhile, the PCR cycle threshold (Ct) value (30.6 ± 4.8 vs. 26.2 ± 4.3, p < 0.05) and IgM titers (2.1 ± 2.8 vs. 0.3 ± 0.6, P < 0.05) of SARS-CoV-2 in LP-IgM positive group was higher than negative group (B).
Recent studies showed that the incidence of COVID-19 co-infection with LP ranged from 0.288–1.1% [1, 2] based on PCR from lower respiratory tract specimens or urine antigen testing, to 12.6–20% [3, 4] based on immune-fluorescence or ELISA serological antibody test. To our knowledge, our study was the first report to confirm false-positive LP-IgM in COVID-19, which was similar to the cross-immune responses in previous studies .
Considering the potential risk of false positive results in COVID-19 patients, we suggest avoiding the immediate testing of LP-IgM or diagnosing Legionella pneumophila infection. Similarly, we advise against the empirical use of antibiotics such as fluoroquinolones. Instead, we recommend testing respiratory secretions DNA or urine Legionella pneumophila antigen for accurate diagnosis and appropriate treatment. Given the decrease in the incidence of COVID-19, the disease has become a crucial differential diagnosis, highlighting the significance of identifying patients who are admitted to the ICU with COVID-19. Our findings suggest a high positivity rate of LP-IgM in COVID-19 patients, which could serve as a potential risk factor. Therefore, clinicians should consider conducting SARS-CoV-2 testing in LP-IgM-positive patients.
Availability of data and materials
We have no conflicts of interests to disclose of any other funding sources.
Riccò M, Ferraro P, Peruzzi S, Zaniboni A, Ranzieri S (2022) SARS-CoV-2-legionella co-infections: a systematic review and meta-analysis (2020–2021). Microorganisms 10(3):499. https://doi.org/10.3390/microorganisms10030499
Verhasselt HL, Buer J, Dedy J et al (2021) COVID-19 co-infection with Legionella pneumophila in 2 tertiary-care hospitals, Germany. Emerg Infect Dis 27(5):1535–1537. https://doi.org/10.3201/eid2705.203388
Xing QS, Li GJ, Xing YH et al (2020) Precautions are needed for COVID-19 patients with coinfection of common respiratory pathogens. Medrxiv. https://doi.org/10.1101/2020.02.29.20027698v2
Alhoufie ST, Ibrahim NA, Alsharif NH et al (2022) Seroprevalence of community-acquired atypical bacterial pneumonia among adult COVID-19 patients from a single center in Al Madinah Al Munawarah, Saudi Arabia: a retrospective cohort study. Saudi Med J 43(9):1000–1006. https://doi.org/10.15537/smj.2022.43.9.20220379
Phin N, Parry-Ford F, Harrison T et al (2014) Epidemiology and clinical management of Legionnaires’ disease. Lancet Infect Dis 14(10):1011–1021. https://doi.org/10.1016/S1473-3099(14)70713-3
Ethics approval and consent to participate
This study has been approved by the Ethics Committee of Peking Union Medical College Hospital(K23C0322).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
He, Sh., Li, S. & Weng, L. False-positive Legionella pneumophila antibodies in COVID-19 patients. ICMx 11, 29 (2023). https://doi.org/10.1186/s40635-023-00512-8